WE are flying!! More news:
Pathobiotek Diagnostics Announces Agreement and Plan of Merger With Investra Enterprises,
Inc.
HOUSTON--(BW HealthWire)--March 9, 2000--Pathobiotek Diagnostics Inc. (PDI) (OTC BB: PBTK), a developer of products for the diagnosis and evaluation
of treatment for multiple sclerosis (MS) and other immune disorders, today announced that the Company has executed an Agreement and Plan of Merger pursuant to
which Investra Enterprises, Inc., a Florida corporation is merged with and into Pathobiotek Diagnostics Inc.
Pathobiotek Diagnostics Inc. is the surviving corporation in such merger and succeeds as successor registrant, to the existing registration of Investra Enterprises Inc.
under the Securities and Exchange Act of l934. The merger has been consummated and a Form 8K describing the transaction and Pathobiotek Diagnostics Inc. has
been filed with the Securities and Exchange Commission and NASD, and will be available to the public on EDGAR.
The merger will permit Pathobiotek Diagnostics Inc. to satisfy its registration and reporting requirements under the Exchange Act, achieve compliance under the
eligibility rules governing the NASD OTC Bulletin Board, and actively pursue and implement its acquisition program. The stock symbol has been changed to PBTK
from PBTKE.
Pathobiotek Diagnostics Inc. is a product development and technology licensing company, whose current primary objective is the development, licensing and sale of
definitive diagnostics for diseases associated with the human microorganism, Luey. The Company's products find value in diagnostics, therapeutics, research,
technology and veterinary markets.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are
cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products,
increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks
detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
Also see www.pathobiotek.com and www.otcfn.com/pbtk |
